Skip to content

Study · Observational study · 2025

9 results

Comparative effectiveness of GLP-1 RAs and other glucose-lowering therapies among Medicare Advantage beneficiaries with T2D and ASCVD.

Tan X, Liang Y, Xie L, Gutierrez C, Harton J, Muhammad C, Swift C, de Havenon A

Current medical research and opinion1 Oct 2025Cited by 2 (Europe PMC)

PMID41122783 (opens in a new tab)DOI10.1080/03007995.2025.2577762 (opens in a new tab)PepBankPUB-41122783
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes and ASCVD, semaglutide had lower risk of all assessed cardiovascular outcomes than SGLT2 inhibitors.

    In plain wordsIn adults with type 2 diabetes and heart disease, semaglutide was linked to lower risk of all heart and stroke outcomes than SGLT2 inhibitors.

    Peptide
    Semaglutide
    Outcome
    DecreaseCardiovascular outcomes, semaglutide vs SGLT2 inhibitors
    Study

    n: not reported in source

    Comparator
    SGLT2 inhibitors
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Semaglutide had lower risk of all CV outcomes vs SGLT2is.
    2 context sentences
    Summary · context
    This observational cohort study included MA beneficiaries with T2D and ASCVD within Optum's de-identified Clinformatics Data Mart Database (01/2007-03/2024).
    Summary · context
    Propensity score matching was used to compare adults initiating OW GLP-1 RAs or ONIGLTs.

Studies that did not test the peptide alone8

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes and ASCVD, once-weekly GLP-1 receptor agonists as a class had 18% lower risk of ischemic stroke than other non-insulin glucose-lowering therapies.

    In plain wordsIn adults with diabetes and heart disease, weekly GLP-1 drugs as a class were linked to 18% lower stroke risk than other glucose-lowering drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseIschemic stroke risk, GLP-1 RAs vs other glucose-lowering drugs
    Study

    n: not reported in source

    Comparator
    Other non-insulin glucose-lowering therapies
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Risk reduction
    18%
    ischemic stroke

    Source sentences

    Summary
    Compared with ONIGLTs, OW GLP-1 RAs had 18% lower risk for IS
    2 context sentences
    Summary · context
    This observational cohort study included MA beneficiaries with T2D and ASCVD within Optum's de-identified Clinformatics Data Mart Database (01/2007-03/2024).
    Summary · context
    Propensity score matching was used to compare adults initiating OW GLP-1 RAs or ONIGLTs.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes and ASCVD, once-weekly GLP-1 receptor agonists as a class had 14% lower risk of myocardial infarction than other non-insulin glucose-lowering therapies.

    In plain wordsIn adults with diabetes and heart disease, weekly GLP-1 drugs as a class were linked to 14% lower heart attack risk than other glucose-lowering drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseMyocardial infarction risk, GLP-1 RAs vs other glucose-lowering drugs
    Study

    n: not reported in source

    Comparator
    Other non-insulin glucose-lowering therapies
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Risk reduction
    14%
    myocardial infarction

    Source sentences

    Summary
    Compared with ONIGLTs, OW GLP-1 RAs had 18% lower risk for IS, 14% lower for MI, 17% lower for 2-point MACE, 28% lower for 3-point MACE, and 27% lower for 5-point MACE.
    2 context sentences
    Summary · context
    This observational cohort study included MA beneficiaries with T2D and ASCVD within Optum's de-identified Clinformatics Data Mart Database (01/2007-03/2024).
    Summary · context
    Propensity score matching was used to compare adults initiating OW GLP-1 RAs or ONIGLTs.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 04HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes and ASCVD, once-weekly GLP-1 receptor agonists as a class had 17% lower risk of 2-point MACE than other non-insulin glucose-lowering therapies.

    In plain wordsIn adults with diabetes and heart disease, weekly GLP-1 drugs as a class were linked to 17% lower 2-point MACE risk than other glucose-lowering drugs.

    Peptide
    Semaglutide
    Outcome
    Decrease2-point MACE risk, GLP-1 RAs vs other glucose-lowering drugs
    Study

    n: not reported in source

    Comparator
    Other non-insulin glucose-lowering therapies
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Risk reduction
    17%
    2-point MACE

    Source sentences

    Summary
    Compared with ONIGLTs, OW GLP-1 RAs had 18% lower risk for IS, 14% lower for MI, 17% lower for 2-point MACE, 28% lower for 3-point MACE, and 27% lower for 5-point MACE.
    2 context sentences
    Summary · context
    This observational cohort study included MA beneficiaries with T2D and ASCVD within Optum's de-identified Clinformatics Data Mart Database (01/2007-03/2024).
    Summary · context
    Propensity score matching was used to compare adults initiating OW GLP-1 RAs or ONIGLTs.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes and ASCVD, once-weekly GLP-1 receptor agonists as a class had 28% lower risk of 3-point MACE than other non-insulin glucose-lowering therapies.

    In plain wordsIn adults with diabetes and heart disease, weekly GLP-1 drugs as a class were linked to 28% lower 3-point MACE risk than other glucose-lowering drugs.

    Peptide
    Semaglutide
    Outcome
    Decrease3-point MACE risk, GLP-1 RAs vs other glucose-lowering drugs
    Study

    n: not reported in source

    Comparator
    Other non-insulin glucose-lowering therapies
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Risk reduction
    28%
    3-point MACE

    Source sentences

    Summary
    Compared with ONIGLTs, OW GLP-1 RAs had 18% lower risk for IS, 14% lower for MI, 17% lower for 2-point MACE, 28% lower for 3-point MACE, and 27% lower for 5-point MACE.
    2 context sentences
    Summary · context
    This observational cohort study included MA beneficiaries with T2D and ASCVD within Optum's de-identified Clinformatics Data Mart Database (01/2007-03/2024).
    Summary · context
    Propensity score matching was used to compare adults initiating OW GLP-1 RAs or ONIGLTs.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 06HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes and ASCVD, once-weekly GLP-1 receptor agonists as a class had 27% lower risk of 5-point MACE than other non-insulin glucose-lowering therapies.

    In plain wordsIn adults with diabetes and heart disease, weekly GLP-1 drugs as a class were linked to 27% lower 5-point MACE risk than other glucose-lowering drugs.

    Peptide
    Semaglutide
    Outcome
    Decrease5-point MACE risk, GLP-1 RAs vs other glucose-lowering drugs
    Study

    n: not reported in source

    Comparator
    Other non-insulin glucose-lowering therapies
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Risk reduction
    27%
    5-point MACE

    Source sentences

    Summary
    Compared with ONIGLTs, OW GLP-1 RAs had 18% lower risk for IS, 14% lower for MI, 17% lower for 2-point MACE, 28% lower for 3-point MACE, and 27% lower for 5-point MACE.
    2 context sentences
    Summary · context
    This observational cohort study included MA beneficiaries with T2D and ASCVD within Optum's de-identified Clinformatics Data Mart Database (01/2007-03/2024).
    Summary · context
    Propensity score matching was used to compare adults initiating OW GLP-1 RAs or ONIGLTs.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  6. 07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes and ASCVD, once-weekly GLP-1 receptor agonists as a class had 14% lower risk of 2-point MACE than SGLT2 inhibitors.

    In plain wordsIn adults with diabetes and heart disease, weekly GLP-1 drugs as a class were linked to 14% lower 2-point MACE risk than SGLT2 inhibitors.

    Peptide
    Semaglutide
    Outcome
    Decrease2-point MACE risk, GLP-1 RAs vs SGLT2 inhibitors
    Study

    n: not reported in source

    Comparator
    SGLT2 inhibitors
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Risk reduction
    14%
    2-point MACE

    Source sentences

    Summary
    Compared with SGLT2is, OW GLP-1 RAs had 14% lower risk of 2-point MACE, 15% lower risk of 3-point MACE, and 14% lower risk of 5-point MACE.
    2 context sentences
    Summary · context
    This observational cohort study included MA beneficiaries with T2D and ASCVD within Optum's de-identified Clinformatics Data Mart Database (01/2007-03/2024).
    Summary · context
    Propensity score matching was used to compare adults initiating OW GLP-1 RAs or ONIGLTs.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 08HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes and ASCVD, once-weekly GLP-1 receptor agonists as a class had 15% lower risk of 3-point MACE than SGLT2 inhibitors.

    In plain wordsIn adults with diabetes and heart disease, weekly GLP-1 drugs as a class were linked to 15% lower 3-point MACE risk than SGLT2 inhibitors.

    Peptide
    Semaglutide
    Outcome
    Decrease3-point MACE risk, GLP-1 RAs vs SGLT2 inhibitors
    Study

    n: not reported in source

    Comparator
    SGLT2 inhibitors
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Risk reduction
    15%
    3-point MACE

    Source sentences

    Summary
    Compared with SGLT2is, OW GLP-1 RAs had 14% lower risk of 2-point MACE, 15% lower risk of 3-point MACE, and 14% lower risk of 5-point MACE.
    2 context sentences
    Summary · context
    This observational cohort study included MA beneficiaries with T2D and ASCVD within Optum's de-identified Clinformatics Data Mart Database (01/2007-03/2024).
    Summary · context
    Propensity score matching was used to compare adults initiating OW GLP-1 RAs or ONIGLTs.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 09HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome

    In adults with type 2 diabetes and ASCVD, once-weekly GLP-1 receptor agonists as a class had 14% lower risk of 5-point MACE than SGLT2 inhibitors.

    In plain wordsIn adults with diabetes and heart disease, weekly GLP-1 drugs as a class were linked to 14% lower 5-point MACE risk than SGLT2 inhibitors.

    Peptide
    Semaglutide
    Outcome
    Decrease5-point MACE risk, GLP-1 RAs vs SGLT2 inhibitors
    Study

    n: not reported in source

    Comparator
    SGLT2 inhibitors
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Risk reduction
    14%
    5-point MACE

    Source sentences

    Summary
    Compared with SGLT2is, OW GLP-1 RAs had 14% lower risk of 2-point MACE, 15% lower risk of 3-point MACE, and 14% lower risk of 5-point MACE.
    2 context sentences
    Summary · context
    This observational cohort study included MA beneficiaries with T2D and ASCVD within Optum's de-identified Clinformatics Data Mart Database (01/2007-03/2024).
    Summary · context
    Propensity score matching was used to compare adults initiating OW GLP-1 RAs or ONIGLTs.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.